Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated December 9, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing details transactions executed under a specific sub-programme initiated on November 11, 2024, and provides an aggregate update on the broader 12-month repurchase plan that began on February 6, 2024.
Key Financial Metrics and Share Repurchase Activity
The filing focuses exclusively on capital allocation via share buybacks rather than operational financial metrics such as revenue or profit.
- Overall Programme Cap: Up to DKK 20 billion over a 12-month period starting February 6, 2024.
- Current Sub-Programme Cap: Up to DKK 3,136,206,122.30 for the period from November 11, 2024, to February 3, 2025.
- Total Repurchased (Since Feb 6, 2024): 21,818,078 B shares.
- Total Value Repurchased (Since Feb 6, 2024): DKK 18,072,465,051.
- Average Purchase Price (Since Feb 6, 2024): DKK 828.33 per B share.
- Treasury Shares Held: 22,962,636 B shares (0.5% of total share capital).
Recent transactions between December 2 and December 6, 2024, involved the purchase of 490,974 B shares with an average price ranging between DKK 769.13 and DKK 784.58.
Material Changes
The filing does not report material changes to the company's business operations, revenue, or profitability. The primary change reported is the incremental increase in treasury shares and the reduction of cash reserves due to the execution of the share repurchase programme. As of December 6, 2024, the company has utilized approximately 90% of the total DKK 20 billion authorization for the 12-month period.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the remaining authorized amount of the DKK 20 billion programme through the 12-month period ending February 5, 2025. The company states its purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
Risks and Contingencies: The filing does not disclose new risks or contingencies. It notes that the repurchase programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. The filing text does not provide specific values for liquidity, debt, or cash flow beyond the transaction values of the buybacks.
Key Facts for Investor Verification
- Verify the remaining authorization under the DKK 20 billion share repurchase programme (approximately DKK 1.93 billion remaining as of Dec 6, 2024).
- Confirm the total number of treasury shares held (22,962,636 B shares) and its impact on earnings per share.
- Review the average purchase price of DKK 828.33 against current market prices to assess the valuation of the buyback.
- Check the company's cash position in the most recent quarterly or annual report to ensure sufficient liquidity remains after the DKK 18 billion in buybacks.
- Monitor the timeline for the conclusion of the current 12-month programme (February 5, 2025).